The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Immunoglobulin A IgA Vasculitis Market Be By 2030 Compared To Its 2026 Market Size?
The immunoglobulin a iga vasculitis market has experienced robust expansion in recent years. Its value is anticipated to rise from $1.63 billion in 2025 to $1.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. This historical development can be ascribed to several contributing factors: a better clinical understanding of IgA-mediated autoimmune conditions, an uptick in the diagnosis of pediatric vasculitis incidents, broader application of corticosteroids and immunosuppressant therapies, the expansion of hospital-based services for autoimmune care, and the deepening expertise in nephrology.
The market size for immunoglobulin a iga vasculitis is anticipated to experience substantial expansion over the next few years. It is projected to ascend to $2.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This expected growth throughout the forecast period stems from escalating research into novel immunomodulatory medications, the increasing integration of personalized autoimmune treatments, a rising commitment to long-term renal protection, the broadening of biologic treatment pipelines, and enhancements in diagnostic imaging and biopsy methods. Key trends during this period involve a greater focus on early and precise disease detection, the growing uptake of targeted immunosuppressive therapies, an expanding application of biomarker-based disease monitoring, the diversification of personalized treatment strategies, and an increased emphasis on managing renal outcomes.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Key Drivers Are Affecting The Immunoglobulin A IgA Vasculitis Market Development?
The increasing occurrence of autoimmune diseases is projected to drive the expansion of the immunoglobulin A (IgA) vasculitis market in the future. Autoimmune diseases are conditions where the body’s immune system mistakenly targets its own healthy cells, tissues, or organs, rather than safeguarding against infections and external threats. The growing prevalence of these disorders is mainly attributed to increased exposure to pollutants, which can disrupt immune regulation and trigger abnormal reactions. Immunoglobulin A (IgA) vasculitis supports the understanding and potential treatment of autoimmune diseases by initiating an immune response that leads to inflammation in small blood vessels. For instance, in February 2024, the Vasculitis Foundation, a US-based non-profit organization, stated that the annual incidence of IgA vasculitis in U.S. adults is approximately 2 cases per 100,000, although rates differ significantly worldwide, ranging from about 60 to 550 cases per million. Therefore, the rising incidence of autoimmune diseases is fueling the growth of the immunoglobulin A (IgA) vasculitis market.
How Is The Immunoglobulin A IgA Vasculitis Market Broken Down By Segment Categories?
The immunoglobulin a iga vasculitis market covered in this report is segmented –
1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy
2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy
3) By Route Of Administration: Oral, Injectables
4) By End User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil
2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration
3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management
4) By Immunosuppressive Therapy: Methotrexate, Rituximab
What Trends Are Transforming The Immunoglobulin A IgA Vasculitis Market?
Key companies active in the immunoglobulin A (IgA) vasculitis market are concentrating on creating novel therapies, such as targeted biologics and immunomodulators, to mitigate inflammation and avert renal complications. These targeted biologics and immunomodulators represent advanced treatments designed to modulate specific immune pathways, thereby reducing inflammation and preventing immune-mediated damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical company based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for addressing primary immunoglobulin A nephropathy (IgAN). Vanrafia is a once-daily, oral, selective endothelin A receptor antagonist developed to decrease proteinuria in adults with primary IgAN who are susceptible to rapid disease progression. It can be seamlessly integrated into existing supportive care regimens without requiring a risk evaluation and mitigation strategy (REMS).
Which Players Are Present In The Immunoglobulin A IgA Vasculitis Market Space?
Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd
Get The Full Immunoglobulin A IgA Vasculitis Market Report:
Which Region Holds The Highest Market Share In The Immunoglobulin A IgA Vasculitis Market?
North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Immunoglobulin A IgA Vasculitis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Immunoglobulin A IgA Vasculitis Market 2026, By The Business Research Company
Intravenous Immunoglobulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Immunodiagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report
Veterinary Autoimmune Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model